Starpharma signs DEP Research Agreement with US Biopharma Co

On 7 December 2021 Starpharma reported that it has signed an exploratory DEP Research Agreement with Genentech, a member of the Roche Group, with an initial focus on evaluating DEP (dendrimer based) drug conjugates (Press release, Starpharma, DEC 7, 2021, View Source [SID1234634709]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Starpharma also has a number of existing DEP partnerships with leading international pharmaceutical companies, including AstraZeneca, Merck & Co., Inc., Chase Sun, as well as several undisclosed partnerships.

Starpharma’s DEP technology has already yielded four clinical stage products.

About DEP
Starpharma’s proprietary dendrimer-based DEP platform has broad commercial applicability in drug delivery by enhancing the therapeutic utility of drugs through improved solubility, efficacy and pharmacokinetic control, reductions in certain toxicities (e.g., bone marrow toxicity) and creating a unique intellectual property position. The novel DEP platform has shown reproducible advantages across a wide range of drug classes and can be utilised with both small molecule drugs, peptides and proteins, and in the development of unique DEP based ADCs, radiotherapies and radiodiagnostics.

Potential benefits of DEP dendrimer drug delivery include:
• Improving efficacy
• Improving therapeutic index
• Reducing toxic side effects of drugs
• Enhanced and controllable pharmacokinetics
• Tumour targeting
• Increased aqueous solubility, avoiding the need for toxic excipients (e.g., polysorbate-80) thus reducing the need for steroid pre-treatment
• Delivering a variety of payloads (small molecules, proteins, radio-isotopes)
• Creation of new intellectual property

Starpharma has three phase 2 clinical stage DEP assets, multiple preclinical DEP programs, and has applied its DEP technology in partnership with pharmaceutical companies for many different applications (passive and targeted ADC and radiotheranostics) and diseases (oncology and nononcology applications).

Entry into a Material Definitive Agreement

On December 7, 2021, Propanc Biopharma, Inc. (the "Company") reported that it entered into a securities purchase agreement (the "Purchase Agreement") with ONE44 Capital LLC, ("ONE44"), pursuant to which ONE44 purchased a convertible promissory note (the "Note") from the Company in the aggregate principal amount of $170,000, such principal and the interest thereon convertible into shares of the Company’s common stock at the option of ONE44 (Filing, 8-K, Propanc, DEC 7, 2021, View Source [SID1234597015]). The transaction contemplated by the Purchase Agreement is expected to close on or about December 13, 2021. The Company intends to use the net proceeds ($153,000) from the Note for general working capital purposes. The Note contains an original issue discount amount of $17,000.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The maturity date of the Note is December 7, 2022 (the "Maturity Date"). The Note shall bear interest at a rate of 10% per annum, which interest may be paid by the Company to ONE44 in shares of common stock, but shall not be payable until the Note becomes payable, whether at the Maturity Date or upon acceleration or by prepayment, as described below. ONE44 has the option to convert all or any amount of the principal face amount of the Note, starting on June 5, 2022, and ending on the later of the Maturity Date and the date of payment of the Default Amount (as defined below) is paid if an event of default occurs, for shares of the Company’s common stock at the then-applicable conversion price. The conversion price for the Note shall be equal to the Conversion Price (as defined herein) (subject to equitable adjustments for stock splits, stock dividends or rights offerings by the Company relating to the Company’s securities or the securities of any subsidiary of the Company, combinations, recapitalization, reclassifications, extraordinary distributions and similar events). The "Conversion Price" shall mean 65% multiplied by the lowest closing bid price of the Company’s common stock as reported on the OTC Markets. Notwithstanding the foregoing, ONE44 shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by ONE44 and its affiliates, exceeds 4.99% of the outstanding shares of the Company’s common stock.

The Note may be prepaid until 180 days from the issuance date. If the Note is prepaid within 60 days of the issuance date, then the prepayment premium shall be 120% of the face amount plus any accrued interest, if prepaid after 60 days from the issuance date, but less than 120 days from the issuance date, then the prepayment premium shall be 130% of the face amount plus any accrued interest, if prepaid after 120 days from the issuance date, up to 180 from the issuance date, then the prepayment premium shall be 135% of the face amount plus any accrued interest. So long as the Note is outstanding, the Company covenants not to, without prior written consent from ONE44, sell, lease or otherwise dispose of all or substantially all of its assets outside the ordinary course of business which would render the Company a "shell company" as such term is defined in Rule 144.

Other than as described above, the Note contains certain events of default, including failure to timely issue shares upon receipt of a notice of conversion, as well as certain customary events of default, including, among others, breach of covenants, representations or warranties, insolvency, bankruptcy, liquidation and failure by the Company to pay the principal and interest due under the Note.

Upon the occurrence and during the continuation of certain events of default, the Note will accrue an interest rate of 24%.

The Note was issued, and any shares to be issued pursuant to any conversion of the Note shall be issued, in a private placement in reliance upon an exemption from registration provided by Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder.

The foregoing description of the Note and the Purchase Agreement does not purport to be complete and is qualified in their entirety by reference to the full text of the Purchase Agreement and the Note, which are filed as Exhibits 4.1 and 10.1, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.

Expanded Heart Protection Discovery for Zantrene

On December 7, 2021 Race Oncology Limited ("Race") reported additional interim results from the Zantrene (bisantrene dihydrochloride) preclinical heart safety research program led by eminent cardiotoxicity researchers, Associate Professors Aaron Sverdlov and Doan Ngo, in collaboration with cancer scientist Associate Professor Nikki Verrills, at The University of Newcastle (ASX announcement: 28 April 2021) (Press release, Race Oncology, DEC 7, 2021, View Source [SID1234596735]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This research has found that Zantrene is able to also protect heart muscle cells from a new class of anti-cancer drug (carfilzomib) induced cell death while improving the carfilzomib-mediated killing of cancer cells.

Carfilzomib (trademark Kyprolis) is a highly effective anti-cancer drug used in the treatment of multiple myeloma (a dangerous blood cancer), but it can cause serious and permanent damage to the heart in many patient1. The risk of cardiac damage is so great that its use in older patients with pre-existing heart disease is often contraindicated2.

"Carfilzomib is a highly effective anti-cancer drug, but it’s use is limited due to cardiotoxicity. Our laboratory has tested numerous drug candidates over the years, we observe that Zantrene has: 1. potent anti-cancer effects; 2. synergistic anti-cancer effects with both carfilzomib and doxorubicin; and 3. cardioprotective effects against both carfilzomib and doxorubicin-induced cardiotoxicity. Zantrene was shown to salvage over 30% of carfilzomib-induced human heart cell from death. These results are genuinely remarkable, as with other clinically used cardioprotective drugs, we only observe a 10-15% protection from heart cell damage.

Zantrene is the first anti-cancer agent that we have found to exhibit a cardioprotective profile while being synergistically effective as an anti-cancer treatment. These results give hope to the millions of patients living with cancer that once they survive cancer, they may not have to live with heart disease."

Associate Professor Doan Ngo
While Zantrene’s improved heart safety compared to anthracyclines was demonstrated in more than 50 human clinical trial3,4, and has been shown in preclinical studies to protect heart muscle cells from anthracycline-induced death (ASX Announcement: 22 November 2021), the question as to whether Zantrene could help prevent cardiac damage caused by other classes of heart damaging cancer drugs had not been addressed.

"The expansion of Zantrene’s cardio-protection and anti-cancer synergy beyond the anthracyclines into the completely new drug class of proteasome inhibitors is unexpected. This discovery opens new clinical development pathways and partnering opportunities for Zantrene beyond those already identified by Race."

CSO Dr Daniel Tillett
"This additional result further underscores the potential patient utility and commercial applicability for Zantrene. We will be allocating additional resources to ensure this discovery can be comprehensively addressed."

Chief Executive Officer, Mr Phillip Lynch
Study Background
Multiple Myeloma
Multiple myeloma is dangerous leukaemia caused by the uncontrolled proliferation of the plasma white blood cells. It usually occurs in people aged over 60 and is more common in men. Multiple myeloma accounts for 10% of all blood cancers and is responsible for 1.8% of all new cancer cases in the United States, with a lifetime risk of 0.8% and a 5-year survival of 55.6% in 20215.

Carfilzomib mechanism of action and use
Carfilzomib is an intravenous drug for treating multiple myeloma in patients with relapsed or refractory disease after at least one previous therapy. It is given in combination with dexamethasone or with lenalidomide and dexamethasone6.

Originally developed by Proteolix before being acquired by Onyx Pharmaceuticals in 2009, carfilzomib is currently owned by Amgen after their acquisition of Onyx in 20137. Carfilzomib’s patent protection is expected to expire in 2025.

Carfilzomib is a 20S proteasome inhibitor that works by interfering with the system for breaking down proteins within cells. One of the hallmarks of cancer is the loss of control of normal protein synthesis and an increase in misfolded and damaged proteins that need to be removed. Inhibition of the 20S proteasome prevents these damaged proteins from being degraded, ultimately resulting in death of the cancer cells8.

Carfilzomib is administered to multiple myeloma patients in 28-day cycles. An intravenous infusion is given on two consecutive days each week for three weeks followed by a 12-day rest period. The annual cost of carfilzomib for a multiple myeloma patient is over US$300,000, with many patients treated for two or more years9.

Carfilzomib-induced cardiotoxicity
While effective in treating multiple myeloma, carfilzomib comes with significant risk of permanent heart damage. An analysis of the Phase 2 carfilzomib studies found of the 526 patients treated, 22% (n=116) of patients developed cardiac side-effects, 13.3% (n=70) showed arrhythmia, mainly atrial fibrillation, 7.2% (n=38) exhibited heart failure, 2% (n=9) developed treatment-associated cardiomyopathy, and 3% (n=18) suffered from ischemic heart disease2. Most cardiovascular events occurred early, with the first few doses administered10.

A history of atrial fibrillation/flutter or heart failure was more prevalent in patients experiencing cardiovascular events, emphasizing the importance of closely monitoring patients given carfilzomib11. Ionising radiation of the chest and/or anthracycline treatment also increases the risk of carfilzomib-induced cardiotoxicity, while biomarkers and echocardiography are not able to identify the patients most at risk for cardiovascular events12.

Study Highlights
1. Zantrene protects cardiomyocytes from carfilzomib-induced cell death
This study found Zantrene was able to protect or rescue primary human heart muscle (cardiomyocyte) cells from carfilzomib-induced cell death. Incubation of cardiomyocytes in the presence of 1000 nM carfilzomib for 72 hours resulted in 80% cell death (Fig. 2). Protection from cardiomyocyte cell death was observed upon the addition of 250 nM Zantrene and increased further with higher concentrations, reaching 50% survival (2.5-fold increase) at 1000 nM, a concentation that is less than 15% of the maximium achievable and tolerated dose in humans13.

Figure 2. Primary human cardiomyocyte cell viability when cultured in the presence of 0-5000 nM of Zantrene and 1000 nM carfilzomib for 72 hours. Data is the average of five independent replicates, each performed in triplicate. Bars show the standard error.

2. Zantrene is highly active in killing multiple myeloma cancer cells
Zantrene was found to be highly active in killing the multiple myeloma cell line H929, with an IC50 below 15 nM (Fig. 3). Addition of only 10 nM carfilzomib to 15 nM of Zantrene resulted in 100% cell death (data not shown). Experiments are currently underway to determine the optimal synergistic combinations of these two drugs in multiple myeloma cell lines.

Figure 3. H929 Multiple Myeloma cell viability when cultured in the presence of 0-5000 nM of Zantrene for 72 hours.

3. Zantrene synergises with carfilzomib to better kill breast cancer cells
While carfilzomib has shown preclinical promise as a treatment for solid tumours including breast cancer, it has proven too toxic in patients to be used in the clinic8. This study examined potential synergy between Zantrene and carfilzomib. Inclusion of low concentrations of Zantrene (< 125 nM) resulted in significant breast cancer cell death in the presence of low concentrations of carfilzomib (Table 1). This synergy was not limited to the MB-231 cell line as similar results were seen using MCF7 cells (data not shown).

Table 1. MB-231 breast cancer cell viability (%) when cultured in the presence of increasing concentrations of Zantrene and carfilzomib. Red shows drug combinations that result in high cell killing.

Crown Bioscience Expands UK Facilities to Enable Growth of In Vivo Services

On December 7, 2021 Crown Bioscience, a JSR Life Sciences company and leading contract research organization (CRO) in preclinical and translational drug development services, reported that it has completed the expansion and renovation of its Crown Bioscience United Kingdom facility (Press release, Crown Bioscience, DEC 7, 2021, View Source [SID1234596590]). The additional laboratory and office space will increase capacity and expand the company’s current in vivo offering by 30 percent and provide dedicated space for a newly acquired high frequency ultrasound unit – a specialized high-resolution imaging device designed to increase the utility of two- and three-dimensional imaging without the need for cell line-tagging, coupled with high precision guided inoculation/dosing of orthotopic and metastatic models.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This expansion is a critical step in our ability to provide additional imaging modalities to better visualize and understand tumor progression and response to potential therapies," said Yinfei Yin, PhD, General Manager at Crown Bioscience UK. "This additional imaging platform allows us to perform cutting-edge preclinical studies, offering our customers advanced insights on potential drug candidates before they enter clinical trials."

The Company’s UK site leverages more than 15 years of experience in in vivo optical imaging, including bioluminescence, fluorescence and microCT modalities. Specifically, the addition of high frequency ultrasound will enable better longitudinal evaluation of tumor growth and earlier, more detailed analytics on the tumor microenvironment.

"This site expansion is driven by increased customer demand for access to Crown Bioscience’s in vivo services from the UK and mainland Europe, and allows us to build upon our innovative foundation to develop additional industry-leading technologies," said Armin Spura, PhD, Chief Executive Officer of Crown Bioscience. "Following our recent acquisition of OcellO B.V. and launch of our 3D Ex Vivo Patient Tissue Platform, this milestone enables Crown Bioscience to continue to use the power of partnership to unlock breakthroughs in drug discovery and, ultimately, to provide patients with better treatment options."

Crown Bioscience UK serves customers advancing preclinical and clinical oncology and immuno-oncology studies. The site offers a comprehensive suite of in vivo models, including PDX, CDX and syngeneic portfolios incorporating orthotopic, metastatic, and systemic variations, as well as in vitro and ex vivo services, such as cell viability, invasion/migration assays, immunoassays, 3D-TGA and combination studies/analysis.

IDEAYA Reports Clinical Data from Phase 2 Expansion Dose of Darovasertib and Crizotinib Synthetic Lethal Combination in Heavily Pre-Treated Metastatic Uveal Melanoma

On December 7, 2021 IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, reported a clinical data update for the Phase 1/2 trial evaluating darovasertib and crizotinib synthetic lethal combination in metastatic uveal melanoma (MUM) patients (Press release, Ideaya Biosciences, DEC 7, 2021, View Source [SID1234596581]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The partial responses, percentage of patients with tumor shrinkage and disease control rate observed from the darovasertib and crizotinib synthetic lethal combination in heavily pre-treated MUM patients represents a new clinical efficacy benchmark and provides an opportunity to deliver meaningful patient impact in this high unmet medical need patient population," said Meredith McKean, M.D., Sarah Cannon Research Institute at Tennessee Oncology, Associate Director, Melanoma and Skin Cancer Research.

"These data provide clinical proof-of-concept for the PKC and cMET synthetic lethal combination, and further validate IDEAYA’s synthetic lethality platform. We look forward to exploratory evaluation of this novel PKC and cMET synthetic lethal combination in other potential tumor settings, including GNAQ/11 skin melanoma and MET-amplified and MET high expression tumors," said Yujiro S. Hata, President and Chief Executive Officer of IDEAYA Biosciences.

There are currently no FDA approved therapies for metastatic uveal melanoma or GNAQ/GNA11 solid tumors, highlighting the high unmet medical need. The historical overall response rate (ORR) in metastatic uveal melanoma has generally been reported with an ORR from approximately 0 to 5%, including: pembrolizumab and tebentafusp (each ~5%); MEK inhibitor selumetinib in combination with dacarbazine (3%); and cMET inhibitor cabozantinib monotherapy (~0%).

Darovasertib (IDE196) is a small molecule, potential first-in-class PKC inhibitor. IDEAYA is evaluating the synthetic lethal combination of darovasertib and crizotinib, a small molecule cMET inhibitor, pursuant to a clinical trial collaboration and drug supply agreement with Pfizer. The companies have agreed to support a target enrollment of approximately 40 patients into the ongoing Phase 1/2 clinical combination arm in MUM.

Clinical Data Update – Darovasertib and Crizotinib Combination

At the time of the data and analyses cutoff on November 25, 2021, twenty-two (22) heavily pre-treated (91% with prior therapies, and 59% with 2 or more prior therapies) MUM patients had enrolled in the darovasertib and crizotinib combination arm at the expansion dose, with sixteen (16) evaluable patients who have received one or more tumor scans and 6 patients who are awaiting their 1st tumor scan. Thirteen (13) patients have received two or more tumor scans for evaluation of potential responses. Reported data is preliminary and based on an unlocked database. Enrollment in the darovasertib and crizotinib combination arm of the clinical trial is ongoing.

The company observed encouraging clinical activity in Phase 1/2 clinical trial evaluating darovasertib and crizotinib synthetic lethal combination in metastatic uveal melanoma (MUM) patients in the expansion dose cohort.

The preliminary interim data includes:

100% Disease Control Rate (DCR): 16 of 16 evaluable patients with >1 post-baseline scan showed tumor shrinkage as determined by target lesion size reduction;
31% Overall Response Rate (ORR): 4 of 13 patients with > 2 post-baseline scans had a confirmed partial response (PR) as determined by RECIST 1.1 based on investigator or central review; and no patients have come off-treatment prior to the 2nd scan
46% of patients (6 of 13) with > 2 post-baseline scans observed >30% tumor reduction, including one patient with an unconfirmed PR as determined by RECIST 1.1 is awaiting follow-on tumor scan.
These data provide clinical proof-of-concept for the darovasertib and crizotinib synthetic lethal combination treatment. These data also validate the company’s translational research discovery that Phase 1 clinical response to darovasertib monotherapy associated with low cMETactivity, as measured by gene signature score.

The darovasertib and crizotinib combination therapy has a manageable side effect profile in MUM patients (n=22), with a low rate of drug-related serious adverse events (SAE’s); predominantly Grade 1 or 2 drug-related adverse events. Eighteen (18) patients experienced a drug-related AE, of which six (6) patients observed Grade 3, and no patients observed Grade 4 or Grade 5.

Upcoming Milestones

IDEAYA has selected a darovasertib and crizotinib combination expansion dose to support potential registrational studies. The company is targeting regulatory feedback for potential darovasertib and crizotinib combination registrational path in the first half of 2022.

IDEAYA is also targeting a further clinical data readout for the darovasertib and crizotinib combination, including median progression free survival (mPFS) in MUM patients, in the first half of 2022.

Darovasertib Expansion Opportunities

IDEAYA is also evaluating other indications as potential expansion opportunities, including GNAQ/11 mutant skin melanoma being evaluated in an ongoing arm of the current clinical trial, and adjuvant uveal melanoma (UM) that the company anticipates will be initiated through an investigator sponsor clinical trial (IST) in the first half of 2022. The company also has exploratory evaluation ongoing of the PKC-cMET synthetic lethal hypothesis in additional tumor settings with MET-amplification and MET high expression, such as hepatocellular carcinoma (HCC).

IDEAYA Investor Day – Webcast and Conference Call

IDEAYA will host an Investor Day webcast and conference call this morning, December 7, 2021 at 8:30 am ET, to present darovasertib and crizotinib Phase 1/2 clinical efficacy and tolerability data, as well as clinical landscape, potential registrational strategies and expansion opportunities. Presenters at the Investor Day will include Dr. Meredith McKean, M.D., Sarah Cannon Research Institute at Tennessee Oncology, Associate Director, Melanoma and Skin Cancer Research, a key opinion leader and clinical investigator. Yujiro S. Hata, President and Chief Executive Officer, and other members of the IDEAYA management team will also present.

Corporate Updates

IDEAYA’s Darovasertib Investor Day presentation, as well as an updated corporate presentation, will be available on the company’s website, at its Investor Relations portal (View Source) following the Investor Day event at approximately 10:30am ET.

IDEAYA had cash, cash equivalents and marketable securities of approximately $386 million as of September 30, 2021, which it believes will fund its planned operations into 2025.